It's not just death or improvement, it is all the middle ground of increased disability and impairment that it can cause (including swelling and bleeding) can likely leave a person much more disabled and impaired, whilst still alive, than Alzheimer's would itself. That the phase 3 study did not reveal any but already two in an open label, extension study is itself highly concerning, and in my opinion shows this drug is clearly not near being ready for market.

Alzheimer's is bad, but showing at best a modest improvement on oddly chosen end points in early disease whilst risking significantly disabling side effects that works directly against what you hope the drug will achieve makes me concerned.